CCR5抑制剂:即将出现的新药物

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2007-01-01

Reilly O'Neal

{"title":"CCR5抑制剂:即将出现的新药物","authors":"Reilly O'Neal","doi":"","DOIUrl":null,"url":null,"abstract":"A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamentarium this year.","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"19 2","pages":"15-9"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CCR5 inhibitors: up and coming new agents.\",\"authors\":\"Reilly O'Neal\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamentarium this year.\",\"PeriodicalId\":80644,\"journal\":{\"name\":\"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation\",\"volume\":\"19 2\",\"pages\":\"15-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

2003年，随着首个进入抑制剂恩福韦肽(T-20, Fuzeon)的批准，一类新的抗逆转录病毒药物出现了。相当多的研究已经指向发现针对HIV复制的细胞进入阶段的额外药物，CCR5抑制剂-通过一种新的作用机制阻止病毒进入的药物-准备在今年加入抗逆转录病毒药物的行列。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

CCR5 inhibitors: up and coming new agents.

A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamentarium this year.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation

自引率

0.00%

发文量